Compounds as KAT6 inhibitors

Abstract

The present invention provides compounds as KAT6 inhibitors, specifically, compounds having structures as shown in the following formula (I) and formula (XIV), or optical isomers, pharma- ceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof. The compounds can be used to treat or prevent diseases or conditions associated with the activity or expression level of KAT6. [Formula 1] JPEG2024526311000089.jpg3779

Description

[Technical Field]

[0001] The present invention relates to the field of medicinal chemistry, specifically, the present invention relates to novel derivatives containing a tricyclic heteroaryl group, methods for their synthesis, and their application as KAT6 inhibitors in the preparation of drugs for the treatment of various related diseases such as tumors. [Background technology]

[0002] Histone acetyltransferases use acetyl-coenzyme A to transfer acetyl groups to lysine residues on histones or other substrate proteins. Acetylation is a reversible post-translational modification that plays an important role in eukaryotic gene expression, cell cycle, and signal transduction pathways. Based on homology, histone acetyltransferases are classified into four families: the GNAT (Gcn5-related acetyltransferase) family, the p300 / CBP family, the SRC / p160 family, and the MYST (MOZ, Ybf2 / Sas3, Sas2, and Tip60) family. The acetyltransferase activity of MYST family proteins is influenced by the MYST domain (catalytic domain). The MYST domain contains an acetyl-coenzyme A-binding motif and a relatively rare C2HC-type zinc finger structure, which is structurally conserved in MYST family proteins and other histone acetyltransferases. The MYST domain is a hallmark of MYST family proteins.

[0003] KAT6A (lysine acetyltransferase 6A, also known as MOZ) and KAT6B (lysine acetyltransferase 6B, also known as MORF) belong to the MYST family of acetyltransferases. KAT6A undergoes chromosomal translocations in acute myeloid leukemia and undergoes amplification mutations in cancer types such as lung, breast, ovarian, endometrial, bladder, and esophageal cancer. Similarly, KAT6B undergoes chromosomal translocation mutations in various cancer types. MOZ- and MORF-linked fusion proteins identified in acute myeloid leukemia include MOZ-CBP, MOZ-p300, MOZ-TIF2, MOZ-NcoA3, MOZ-LEUTX, and MORF-CBP. MOZ-TIF2 has transforming activity in cultured cells and can induce acute myeloid leukemia in mice. In KAT6A- and KAT6B-amplified tumor cells, KAT6A and KAT6B expression is closely correlated with gene copy number, indicating the existence of selective pressure to maintain their activity during tumorigenesis. Furthermore, in cell proliferation assays, tumor cells with high KAT6A and KAT6B expression usually exhibit a relatively high dependency on KAT6A and KAT6B activity.

[0004] KAT6A and KAT6B typically ubiquitously acetylate histone H3 at lysine 23 (H3K23), but KAT6A can also selectively acetylate H3K9 in its regulatory genes. KAT6A interacts with several transcription factors, such as p53 and RUNX1, to acetylate histone modifications and regulate granule gene expression. KAT6A binds to the proximal promoter of the estrogen receptor α (ERα) gene, activating ERα expression. In breast cancer cells with ER+, KAT6A amplification mutations, or high expression, inhibition of KAT6A acetyltransferase activity or knockdown of KAT6A significantly inhibits breast cancer cell proliferation. Furthermore, KAT6A acetyltransferase activity is essential for promoting the expression of the MEIS1 and HOXa9 genes, two genes that are often overexpressed in some lymphoma and leukemia cells. In a mouse model of MYC-induced lymphoma, deletion of one KAT6A allele significantly prolonged the median survival of the mice. Mutations in the KAT6B allele in mice result in a significant reduction in the division and differentiation of cortical progenitor cells, severely impacting cortical development. KAT6B also plays an important role in maintaining the number of adult neural stem cells. Mutations in the KAT6B gene are also present in several rare types of leukemia.

[0005] Based on the above background, we will develop structurally novel KAT6 inhibitors. Summary of the Invention [Problem to be solved by the invention]

[0006] It is an object of the present invention to provide a novel class of KAT6 inhibitors. [Means for solving the problem]

[0007] A first aspect of the present invention provides a compound having a structure as shown in formula (I) below, or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, or solvate thereof: [ka] In formula (I), A is selected from formula (Ia), formula (Ib), formula (Ic), or formula (Id); [ka] where: [ka] represents the site at which fragment A is linked to the rest of the compound of formula (I); [ka] represents a double or triple bond, and in the case of a triple bond, R 5 is none, B is selected from formula (Ie), formula (If), or formula (Ig); [ka] where: [ka] represents the site at which fragment B is linked to the rest of the compound of formula (I); R 1 is hydrogen or C 1-4 alkyl groups, Each R 2 are each independently hydrogen, halogen, or C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 1-4 Alkoxy C 1-4 Alkyl group, C 1-4 Halogenated Alkoxy C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Halogenated alkenyl groups, C2-4 Alkynyl group, C 3-6 Cycloalkyl groups, 3- to 8-membered heterocyclic groups, aryl groups, heteroaryl groups, CN, OR a , S.R. a , or NR a R a wherein each R a are each independently hydrogen, C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 3-6 a cycloalkyl group, or a 3- to 8-membered heterocyclic group; D is a chemical bond, -O-, -S-, or -NR e - selected from, where R e is hydrogen, C 1-4 Alkyl group, or C 3-6 cycloalkyl groups, and E is selected from C 3-8 Cycloalkyl group, 3-10 membered heterocyclic group, C 3-8 Cycloalkyl C 1-4 Alkyl group, or 3- to 10-membered heterocyclic ring C 1-4 alkyl groups, Each R 3 are each independently hydrogen, halogen, or C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, CN, OR b , S.R. b , N.R. b R b , -C(O)R g , -S(O)2R g , C 3-6 a cycloalkyl group, or a 3- to 8-membered heterocyclic group, or two R 3 are attached to the same carbon atom of a cycloalkyl group or a heterocyclic ring and together with the carbon atom form C=T, where T is O or CR 12 R 13 where R 12 and R 13 are each independently hydrogen, fluorine, or C 1-4 alkyl groups, wherein R 12 or R 13 The alkyl groups above are halogens, C1-4 Halogenated alkyl groups, CN, OR b , S.R. b , N.R. b R b , C 3-6 each R is optionally substituted with one or more groups selected from the group consisting of a cycloalkyl group, a 3- to 8-membered heterocyclic group, an aryl group, or a heteroaryl group; b are each independently hydrogen, C 1-4 Alkyl group, or C 1-4 halogenated alkyl groups; R g is hydrogen, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 selected from a cycloalkyl group, a 3- to 8-membered heterocyclic group, an aryl group, or a heteroaryl group; R 4 and R 5 are each independently hydrogen, C 1-4 Alkyl group, C 3-8 a cycloalkyl group, a 3- to 9-membered heterocyclic group, an aryl group, or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group, or the heteroaryl group is selected from the group consisting of halogen, CN, OR a , S.R. a , N.R. a R a , NO2, -C(O)R m , -C(O)OR a , -S(O)2R m , -C(O)NR a R a , -OC(O)R m , -NR a C(O)R m , -NR a S(O)2R m , C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6optionally substituted with one or more groups selected from the group consisting of a cycloalkyl group, a 3- to 8-membered heterocyclic group, an aryl group, or a heteroaryl group, or the cycloalkyl group or heterocyclic group is substituted with =T, wherein each R a is as defined above, and R m is C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 cycloalkyl groups, T is as defined above; Each R 6 are each independently hydrogen, halogen, or C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, CN, OR b , S.R. b , or NR b R b where each R b is as defined above, M is O or CR h R i where R h and R i are each independently hydrogen, fluorine, or C 1-4 alkyl groups, wherein the alkyl groups are selected from halogen, C 1-4 Halogenated alkyl groups, CN, OR b , S.R. b , N.R. b R b , C 3-6 and optionally substituted with one or more groups selected from the group consisting of a cycloalkyl group, a 3- to 8-membered heterocyclic group, an aryl group, or a heteroaryl group, wherein each R b is as defined above, Each R 7 are each independently hydrogen, halogen, or C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 2-4 Alkenyl group, C 2-4 Alkynyl groups, CN, OR a , S.R. a , N.R.a R a , C 3-6 Cycloalkyl group, 3- to 8-membered heterocyclic group, aryl group, heteroaryl group, or heteroaryl C 1-4 alkyl groups, wherein each R a is as defined above, R 8 and R 9 are each independently hydrogen, fluorine, or C 1-4 Alkyl group, C 1-4 Alkoxy group, hydroxy group, or C 3-6 cycloalkyl groups or R 8 and R 9 together with the carbon atoms to which they are attached form a 3- to 6-membered ring structure, which ring structure optionally contains 0, 1, or 2 heteroatoms selected from N, O, and S; Each R 10 are each independently hydrogen, halogen, or C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-8 membered heterocyclic group, CN, OR a , S.R. a , or NR a R a where each R a is as defined above, X is O, S, or NR n where R n is hydrogen or C 1-4 alkyl groups, Each R 11 are each independently hydrogen, halogen, or C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 Cycloalkyl group, 3-8 membered heterocyclic group, CN, OR a , S.R. a , N.R. c Rc , or -NR d C(O)R g where each R a is as defined above, and each R c are each independently hydrogen, C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 1-4 Alkoxy C 1-4 Alkyl group, C 3-6 R is selected from a cycloalkyl group, a 3- to 8-membered heterocyclic group, an aryl group, or a heteroaryl group; d is hydrogen or C 1-4 alkyl groups, and R g is as defined above, m is selected from 0, 1, 2, 3, or 4; n is selected from 0, 1, 2, 3, or 4; f is selected from 0, 1, 2, or 3; g is selected from 0, 1, 2, 3, or 4; a and b are each independently selected from 0, 1, 2, 3, 4, or 5, with the proviso that a and b cannot simultaneously be selected from 0; h is selected from 0, 1, 2, or 3; j is selected from 0, 1, 2, or 3; k is selected from 0, 1, 2, 3, 4, or 5; wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl groups optionally and independently may further comprise a halogen, C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-8 Cycloalkyl groups, 3- to 8-membered heterocyclic groups, aryl groups, heteroaryl groups, CN, NO2, OR b , S.R. b , N.R. d R d , -C(O)R g , -C(O)OR b, -C(O)NR d R d , -NR d C(O)R g , -NR d S(O)2R g , or -S(O)2R g and wherein R is substituted by 1 to 3 substituents each independently selected from the group consisting of b , R d , and R g is as defined above.

[0008] Unless otherwise specified, the aryl group is an aromatic group containing 6 to 12 carbon atoms, the heteroaryl group is a 5 to 15-membered (preferably 5 to 12-membered) heteroaromatic group, and the ring structure is a saturated or unsaturated ring group with or without heteroatoms.

[0009] In another preferred embodiment, formula (I) is formula (II): [ka] R 2 , R 3 , R 7 , R 8 , R 9 , R 10 , D, E, m, n, h and j are as defined in the first aspect of the invention.

[0010] In another preferred embodiment, E is C 3-6 Cycloalkyl groups, 3- to 6-membered heterocyclic groups, C 3-6 Cycloalkyl C 1-4 Alkyl group, or 3- to 6-membered heterocyclic ring C 1-4 alkyl groups, and each R 3 are each independently hydrogen, halogen, or C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, CN, OR b , -C(O)R g or two R 3are attached to the same carbon atom of a cycloalkyl group or a heterocyclic ring and together with the carbon atom form C=T, where T is O or CR 12 R 13 where R 12 and R 13 are each independently hydrogen, fluorine, or C 1-4 alkyl groups, wherein R 12 or R 13 The alkyl groups above are halogens, C 1-4 Halogenated alkyl groups, OR b , N.R. b R b and each R is optionally substituted with one or more groups selected from the group consisting of b are each independently hydrogen, C 1-4 Alkyl group, or C 1-4 halogenated alkyl groups; R g is hydrogen, C 1-4 Alkyl group, C 3-8 The group is selected from cycloalkyl groups.

[0011] In another preferred embodiment, formula (I) is formula (III): [ka] U is N or CR k where R k is hydrogen, halogen, C 1-4 alkyl groups, Each R 14 are each independently hydrogen, halogen, or C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, CN, OR b , S.R. b , N.R. b R b is selected from p and q are each independently selected from 0, 1, 2, 3, 4, 5, or 6, with the proviso that p and q cannot simultaneously be selected from 0; t is selected from 0, 1, 2, 3, or 4; R2 , R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R b , D, m, h and j are as defined in the first aspect of the invention.

[0012] In another preferred embodiment, formula (I) is formula (IV): [ka] R 2 , R 4 , R 7 , R 8 , R 9 , R 10 , m, h and j are as defined in the first aspect of the invention.

[0013] In another preferred embodiment, formula (I) is formula (V): [ka] R 2 , R 6 , R 7 , R 8 , R 9 , R 10 , R h , R i , a, b, f, g, h, and j are as defined in the first aspect of the invention.

[0014] In another preferred embodiment, formula (I) is formula (VI): [ka] R 2 , R 6 , R 11 , R h , R i , X, a, b, f, g and k are as defined in the first aspect of the invention.

[0015] In another preferred embodiment, formula (I) is formula (VII): [ka] R 2 , R 11 , R 12 , R 13 , D, X, m, and k are as defined in the first aspect of the invention; U, R 14 , p, q, and t are as defined above.

[0016] In another preferred embodiment, formula (I) is formula (VIII): [ka] Each R 2 are each independently hydrogen, halogen, or C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, CN, OR a , S.R. a , or NR a R a wherein each R a are each independently hydrogen, C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 3-6 cycloalkyl groups, and m is selected from 0, 1, or 2; R 4 , R 7 , R 8 , R 9 , R 10 , h and j are as defined in the first aspect of the invention.

[0017] In another preferred embodiment, the R 4 is hydrogen, C 1-4 Alkyl group, C 3-8a cycloalkyl group, a 3- to 9-membered heterocyclic group, an aryl group, or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group, or the heteroaryl group is selected from the group consisting of halogen, CN, OR a , -C(O)R m , -C(O)OR a , -S(O)2R m , C 1-4 Alkyl group, C 3-6 optionally substituted with one or more groups selected from the group consisting of a cycloalkyl group, a 3- to 8-membered heterocyclic group, an aryl group, or a heteroaryl group, or the cycloalkyl group or heterocyclic group is substituted with =T, wherein each R a is as defined above, and R m is C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 cycloalkyl groups, and T is as defined above.

[0018] In another preferred embodiment, the R 2 are each independently hydrogen, halogen, or C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, OR a , C 3-6 It is selected from a cycloalkyl group and a 3- to 8-membered heterocyclic group.

[0019] In another preferred embodiment, the R 7 are each independently hydrogen, halogen, or C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, OR a , S.R. a , N.R. a R a , C 3-6 Cycloalkyl group, 3- to 8-membered heterocyclic group, aryl group, heteroaryl group, or heteroaryl C 1-4 alkyl groups, and each R a are each independently hydrogen, C 1-4 The alkyl group is selected from the group consisting of:

[0020] In another preferred embodiment, formula (I) is formula (IX): [ka] Each R 2 are each independently hydrogen, halogen, or C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 3-6 Cycloalkyl group, or OR a is selected from the group consisting of R 4 is hydrogen, C 1-4 Alkyl group, C 3-8 a cycloalkyl group, a 3- to 9-membered heterocyclic group, an aryl group, or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group, or the heteroaryl group is selected from the group consisting of halogen, CN, OR a , S.R. a , N.R. a R a , -C(O)R m , -C(O)OR a , -S(O)2R m , C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 It is optionally substituted with one or more groups selected from the group consisting of a cycloalkyl group, a 3- to 6-membered heterocyclic group, an aryl group, or a heteroaryl group, or the cycloalkyl group or heterocyclic group is substituted with =T, where T is O or CR 12 R 13 where R 12 and R 13 are each independently hydrogen, fluorine, or C 1-4 alkyl groups, wherein R 12 or R 13 The alkyl groups above are halogens, C 1-4 Halogenated alkyl groups, CN, OR b , S.R. b , N.R. b R band optionally substituted with one or more groups selected from the group consisting of Each R a are each independently hydrogen, C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 3-6 cycloalkyl groups, and each R b are each independently hydrogen, C 1-4 Alkyl group, or C 1-4 halogenated alkyl groups; R m is C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 The group is selected from cycloalkyl groups.

[0021] In another preferred embodiment, formula (I) is formula (X): [ka] Each R 2 are each independently hydrogen, halogen, or C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 3-6 Cycloalkyl group, or OR a is selected from the group consisting of R 4 is hydrogen, C 1-4 Alkyl group, C 3-8 a cycloalkyl group, a 3- to 9-membered heterocyclic group, an aryl group, or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group, or the heteroaryl group is selected from the group consisting of halogen, CN, OR a , S.R. a , N.R. a R a , -C(O)R m , -C(O)OR a , -S(O)2R m , C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6It is optionally substituted with one or more groups selected from the group consisting of a cycloalkyl group, a 3- to 6-membered heterocyclic group, an aryl group, or a heteroaryl group, or the cycloalkyl group or heterocyclic group is substituted with =T, where T is O or CR 12 R 13 where R 12 and R 13 are each independently hydrogen, fluorine, or C 1-4 alkyl groups, wherein R 12 or R 13 The alkyl groups above are halogens, C 1-4 Halogenated alkyl groups, CN, OR b , S.R. b , N.R. b R b and optionally substituted with one or more groups selected from the group consisting of Each R a are each independently hydrogen, C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 3-6 cycloalkyl groups, and each R b are each independently hydrogen, C 1-4 Alkyl group, or C 1-4 halogenated alkyl groups; R m is C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 3-6 The group is selected from cycloalkyl groups.

[0022] In another preferred embodiment, formula (I) is formula (XI): [ka] Each R 2 are each independently hydrogen, halogen, or C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 1-4 Alkoxy C 1-4 Alkyl group, C 1-4 Halogenated Alkoxy C 1-4Alkyl group, C 2-4 Alkenyl group, C 2-4 Halogenated alkenyl groups, C 2-4 Alkynyl group, C 3-6 Cycloalkyl groups, 3- to 8-membered heterocyclic groups, aryl groups, heteroaryl groups, CN, OR a , S.R. a , or NR a R a is selected from the group consisting of R 4 is hydrogen, C 1-4 Alkyl group, C 3-6 cycloalkyl groups, wherein the alkyl or cycloalkyl groups are selected from the group consisting of halogen, CN, OR a , S.R. a , or NR a R a and optionally substituted with one or more groups selected from the group consisting of Each R a are each independently hydrogen, C 1-4 Alkyl group, C 1-4 Halogenated alkyl groups, C 3-6 cycloalkyl groups, m is selected from 0, 1, 2, or 3.

[0023] In another preferred embodiment, formula (I) is formula (XII): [ka] R 2 and R 4 is as defined above.

[0024] In another preferred embodiment, formula (I) is formula (XIII): [ka] R 2 , R 4 , R 11 , X, m and k are as defined in the first aspect of the invention.

[0025] A second aspect of the present invention provides a compound having a structure as shown in formula (XIV) below, or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, or solvate thereof: [ka] G is C 3-8 selected from a cycloalkyl group, a 3- to 10-membered heterocyclic group, an aryl group (preferably benzene or naphthalene), and a heteroaryl group (preferably furan, thiophene, pyridine, pyrimidine, or pyrazine); R 1 , R 2 , R 4 , B, and m are as defined in the first aspect of the invention.

[0026] In another preferred embodiment, the compounds of formula (I) and formula (XIV) are [ka] [ka] [ka] [ka] [ka] is selected from the group consisting of In each of the above compounds, R 2 is selected from H or OMe.

[0027] A third aspect of the present invention provides a pharmaceutical composition comprising a compound according to the first aspect of the present invention, or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, solvate thereof, and a pharmaceutically acceptable carrier.

[0028] A fourth aspect of the present invention provides the use of a compound according to the first aspect of the present invention, or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate or solvate thereof, in the preparation of a pharmaceutical composition for treating a disease, illness or condition associated with KAT6 activity or expression level.

[0029] In another preferred embodiment, the disease, condition, or pathology is selected from the group consisting of various solid tumors and hematological tumors, such as non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, colon cancer, thyroid cancer, embryonal rhabdomyosarcoma, cutaneous granular cell tumor, melanoma, hepatocellular carcinoma, intrahepatic bile duct cancer, rectal cancer, bladder cancer, pharyngeal cancer, breast cancer, vaginal cancer, prostate cancer, testicular cancer, brain tumor, glioma, ovarian cancer, head and neck squamous cell carcinoma, cervical cancer, osteosarcoma, esophageal cancer, kidney cancer, skin cancer, gastric cancer, myeloid leukemia, lymphocytic leukemia, myelofibrosis, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, monocytic leukemia, splenomegaly, eosinophilic leukocytosis syndrome, and bone marrow cancer. DETAILED DESCRIPTION OF THE INVENTION

[0030] After extensive and thorough research, the present inventors have unexpectedly discovered KAT6 inhibitors with novel structures, as well as their preparation methods and applications.The compounds of the present invention can be used to treat various diseases related to the activity of the acetyltransferase.Based on the above findings, the present inventors have completed the present invention.

[0031] term Unless otherwise stated, "or" as used herein has the same meaning as "and / or" (referring to "or" and "and"). Unless otherwise specified, in all compounds of the present invention, each chiral carbon atom (chiral center) can optionally be of the R or S configuration, or a mixture of the R and S configurations.

[0032] As used herein, the term "alkyl group," when used alone or as part of another substituent, refers to a straight-chain (i.e., unbranched) or branched-chain saturated hydrocarbon group containing only carbon atoms, or a combination of straight-chain and branched-chain groups. When the number of carbon atoms is limited before the alkyl group (e.g., C 1-10 ), the alkyl group contains 1 to 10 carbon atoms. For example, C 1-8 Alkyl refers to alkyl groups containing 1 to 8 carbon atoms, including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, or the like.

[0033] As used herein, the term "alkenyl group," whether used alone or as part of another substituent, refers to a straight or branched carbon chain group having at least one carbon-carbon double bond. Alkenyl groups can be substituted or unsubstituted. When the number of carbon atoms is specified before the alkenyl group (e.g., C 2-8 ) refers to the alkenyl group containing 2 to 8 carbon atoms. For example, C 2-8 Alkenyl refers to alkenyl groups containing 2 to 8 carbon atoms, including vinyl, propenyl, 1,2-butenyl, 2,3-butenyl, butadienyl, or the like.

[0034] As used herein, the term "alkynyl group," whether used alone or as part of another substituent, refers to an aliphatic hydrocarbon group having at least one carbon-carbon triple bond. The alkynyl group may be linear or branched, or a combination thereof. When the number of carbon atoms is limited before the alkynyl group (e.g., C 2-8 alkynyl group) refers to the alkynyl group containing 2 to 8 carbon atoms. For example, "C 2-8 The term "alkynyl group" refers to straight or branched chain alkynyl groups having from 2 to 8 carbon atoms, including ethynyl, propynyl, isopropynyl, butynyl, isobutynyl, s-butynyl, t-butynyl, or the like.

[0035] As used herein, the term "cycloalkyl group," used alone or as part of another substituent, refers to groups having saturated or partially saturated monocyclic, bicyclic, or polycyclic (fused, bridged, or spiro) ring systems. When a particular cycloalkyl group is limited in the number of carbon atoms (e.g., C 3-10 ), the cycloalkyl group contains 3 to 10 carbon atoms. In some preferred embodiments, "C 3-8 The term "cycloalkyl group" refers to saturated or partially unsaturated monocyclic or bicycloalkyl groups having 3 to 8 carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, or similar groups. A "spirocycloalkyl group" refers to a bicyclic or polycyclic group in which one carbon atom (called a spiro atom) is shared between monocyclic rings; these may contain one or more double bonds, but none of the rings have a fully conjugated π-electron system. A "fused cycloalkyl group" refers to an all-carbon bicyclic or polycyclic group in which each ring in the system has a pair of adjacent carbon atoms with another ring in the system; one or more rings may contain one or more double bonds, but none of the rings have a fully conjugated π-electron system. A "bridged cycloalkyl group" refers to an all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected; these may contain one or more double bonds, but none of the rings have a fully conjugated π-electron system. All atoms in the cycloalkyl group are carbon atoms. Some examples of cycloalkyl groups are given below, but the present invention is not limited to these cycloalkyl groups. [ka]

[0036] Unless otherwise stated, the following terms used in the specification and claims have the following meanings: "Aryl group" refers to an all-carbon monocyclic or fused polycyclic (i.e., rings sharing pairs of adjacent carbon atoms) group having a conjugated π-electron system, such as phenyl and naphthyl groups. The aryl ring can be fused to other cyclic groups (including saturated and unsaturated rings), but cannot contain heteroatoms such as nitrogen, oxygen, or sulfur, and the point of attachment to the parent must be on a carbon atom within the ring having a conjugated π-electron system. Aryl groups can be substituted or unsubstituted. Some examples of aryl groups are given below, but the present invention is not limited to these aryl groups. [ka]

[0037] The term "heteroaryl group" refers to an aromatic monocyclic or polycyclic group containing one or more heteroatoms (arbitrarily selected from nitrogen, oxygen, and sulfur), or a polycyclic group formed by condensing a heterocyclic group (containing one or more heteroatoms arbitrarily selected from nitrogen, oxygen, and sulfur) with an aryl group, where the linking site is located in the aryl group. The heteroaryl group may be optionally substituted or unsubstituted. Some examples of heteroaryl groups are shown below, but the present invention is not limited to these heteroaryl groups. [ka]

[0038] A "heterocyclic group" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, in which one or more ring atoms are selected from nitrogen, oxygen, or sulfur, and the remaining ring atoms are carbon. Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and homopiperazinyl. A polycyclic heterocyclic group refers to heterocyclic groups containing spiro rings, fused rings, and bridged rings. A "spirocyclic heterocyclic group" refers to a polycyclic heterocyclic group in which each ring in the system shares an atom (called a spiro atom) with the other rings in the system, in which one or more ring atoms are selected from nitrogen, oxygen, or sulfur, and the remaining ring atoms are carbon. A "fused-ring heterocyclic group" refers to a polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with another ring in the system, and one or more rings may contain one or more double bonds, but no ring has a fully conjugated π-electron system, where one or more ring atoms are selected from nitrogen, oxygen, or sulfur, and the remaining ring atoms are carbon. A "bridged-ring heterocyclic group" refers to a polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, and they may contain one or more double bonds, but no ring has a fully conjugated π-electron system, where one or more ring atoms are selected from nitrogen, oxygen, or sulfur, and the remaining ring atoms are carbon. When a heterocyclic group simultaneously contains both saturated and aromatic rings (e.g., when saturated and aromatic rings are fused), the point of attachment to the parent must be on the saturated ring. Note: When the point of attachment to the parent is on the aromatic ring, it is referred to as a heteroaryl group, not a heterocyclic group. Some examples of heterocyclic groups are shown below, but the present invention is not limited to these heterocyclic groups. [ka]

[0039] As used herein, the term "halogen" when used alone or as part of another substituent refers to F, Cl, Br, and I.

[0040] As used herein, the term "substituted" (with or without the modification "optionally") refers to the replacement of one or more hydrogen atoms on a specified group with a specified substituent. Specific substituents are those described above, as appropriate, or in each Example. Unless otherwise specified, a particular optionally substituted group can have a substituent selected from a specified group at any substitutable position of the group, and the substituents can be the same or different at each position. A cyclic substituent, such as a heterocyclic group, can be attached to another ring, such as a cycloalkyl group, to form a spiro-bicyclic system in which the two rings share one common carbon atom. It will be understood by those skilled in the art that the combinations of substituents contemplated by this invention are those that are stable or chemically achievable. The substituents can be, for example, C 1-8 Alkyl group, C 2-8 Alkenyl group, C 2-8 Alkynyl group, C 3-8 Cycloalkyl groups, 3- to 12-membered heterocyclic groups, aryl groups, heteroaryl groups, halogens, hydroxy groups, carboxy groups (-COOH), C 1-8 Aldehyde group, C 2-10 Acyl group, C 2-10 Examples of the hydroxyl group include, but are not limited to, an ester group and an amino group.

[0041] For convenience and common understanding, the terms "optionally substituted" or "optionally substituted" apply only to moieties that are capable of substitution with a substituent, and do not include substitutions that are not scientifically feasible.

[0042] As used herein, unless otherwise specified, the term "pharmaceutically acceptable salt" refers to a salt that is suitable for contact with the tissues of a subject (e.g., a human) without causing undue adverse side effects. In some embodiments, pharmaceutically acceptable salts of certain compounds of the present invention include salts of compounds of the present invention having a basic group (e.g., potassium salt, sodium salt, magnesium salt, calcium salt) or a basic group (e.g., sulfate, hydrochloride, phosphate, nitrate, carbonate).

[0043] Usage: The present invention provides the use of compounds of formula (I), or deuterated derivatives thereof, salts, isomers (enantiomers or diastereomers, if any), hydrates, pharmaceutically acceptable carriers or excipients thereof, for use in inhibiting KAT6. The compounds of the present invention can be used as KAT6 inhibitors.

[0044] The present invention relates to a single inhibitor of KAT6, which aims to prevent, alleviate or cure diseases by regulating the activity of KAT6. The diseases referred to include, but are not limited to, various solid tumors and blood tumors such as non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, colon cancer, thyroid cancer, embryonal rhabdomyosarcoma, cutaneous granular cell tumor, melanoma, hepatocellular carcinoma, intrahepatic bile duct cancer, rectal cancer, bladder cancer, pharyngeal cancer, breast cancer, vaginal cancer, prostate cancer, testicular cancer, brain tumor, glioma, ovarian cancer, head and neck squamous cell carcinoma, cervical cancer, osteosarcoma, esophageal cancer, kidney cancer, skin cancer, gastric cancer, myeloid leukemia, lymphocytic leukemia, myelofibrosis, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, monocytic leukemia, splenomegaly, eosinophilic leukocytosis syndrome, and bone marrow cancer.

[0045] The compounds of the present invention and their deuterated derivatives, as well as pharmaceutically acceptable salts or isomers thereof (if present) or hydrates thereof, and / or compositions can be formulated with pharmaceutically acceptable excipients or carriers, and the resulting compositions can be administered in vivo to mammals, including men, women, and animals, to treat illnesses, symptoms, and diseases. The compositions can be in the form of tablets, pills, suspensions, solutions, emulsions, capsules, aerosols, sterile injectable solutions, sterile powders, and the like. In some examples, the pharmaceutically acceptable excipients are microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, calcium hydrogen phosphate, mannitol, hydroxypropyl-β-cyclodextrin, β-cyclodextrin (increased), glycine, disintegrants (e.g., starch, croscarmellose sodium, complex silicates, and high molecular weight polyethylene glycol), granulation binders (e.g., polyvinylpyrrolidone, sucrose, gelatin, and gum arabic), and lubricants (e.g., magnesium stearate, glycerin, and talc powder). In a preferred embodiment, the pharmaceutical composition is in a dosage form suitable for oral administration, including, but not limited to, tablets, solutions, suspensions, capsules, granules, and powders. The amount of the compound or pharmaceutical composition of the present invention administered to a patient is not fixed, but is typically administered in a pharmaceutically effective amount. The actual amount of compound administered can be determined by a physician based on actual circumstances, including the disease being treated, the selected route of administration, the actual compound administered, and the individual condition of the patient. The dosage of the compound of the present invention will depend on the specific therapeutic application, the method of administration, the patient's condition, and the physician's judgment. The proportion or concentration of the compound of the present invention in a pharmaceutical composition depends on various factors, including the dosage, physical and chemical properties, the route of administration, and the like.

[0046] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (e.g., in the Examples) can be combined with each other to form new or preferred technical inventions.

[0047] Pharmaceutical Compositions and Methods of Administration Since the compounds of the present invention have excellent inhibitory activity against KAT6, the compounds of the present invention and their various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, as well as pharmaceutical compositions containing the compounds of the present invention as active ingredients, can be used to treat, prevent, and alleviate diseases associated with KAT6 activity or expression level.

[0048] The pharmaceutical composition of the present invention contains a safe and effective amount of the compound of the present invention or a pharmacologically acceptable salt thereof and a pharmacologically acceptable excipient or carrier. Here, "safe and effective amount" refers to an amount of the compound sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1 to 2000 mg of the compound / agent of the present invention, more preferably 5 to 200 mg of the compound / agent of the present invention. Preferably, the "single agent" is one capsule or tablet.

[0049] "Pharmaceutically acceptable carrier" refers to one or more compatible solid or liquid fillers or gel substances that must be of sufficient purity and sufficiently low toxicity to be suitable for human use. "Compatibility" refers to the ability of the components of the composition to blend with each other without significantly reducing the efficacy of the compounds of the present invention. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (e.g., Tween®), wetting agents (e.g., sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0050] The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include, but are not limited to, oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.

[0051] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with (a) a filler or compatibilizer, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; (b) a binder, such as hydroxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (c) a humectant, such as glycerin; (d) agar, calcium carbonate, potato starch, or the like. The formulation may be mixed with ingredients such as disintegrating agents such as potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate, (e) retarding solvents such as paraffin, (f) absorption accelerators such as quaternary amine compounds, (g) wetting agents such as cetyl alcohol and glyceryl monostearate, (h) adsorbents such as kaolin, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets, and pills, the dosage form may also contain buffering agents.

[0052] Solid dosage forms such as tablets, sugar pills, capsules, pills, and granules can be prepared with coatings and shell materials, such as enteric coatings and other materials known in the art. They can contain opacifying agents, and the release of the active compound or compounds of such compositions can be delayed in a specific part of the digestive tract. Examples of embedding materials that can be used include polymeric substances and waxes. If necessary, the active compound can be formed into microcapsules with one or more of the above-mentioned excipients.

[0053] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the active compound, the liquid dosage form can contain an inert diluent conventionally used in the art, such as water or other solvents, and solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, or mixtures of these substances.

[0054] Besides these inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents, and perfuming agents. In addition to the active compound, suspensions may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and dehydrated sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar-agar, or mixtures of these substances.

[0055] Compositions for parenteral injection can include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0056] Dosage forms of the compounds of the present invention used for topical administration include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required. The compounds of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds.

[0057] When a pharmaceutical composition is used, a safe and prevalent amount of the compound of the present invention is administered to a mammal (e.g., a human) in need of treatment, where the dosage at the time of administration is a considered effective dose, and for a person weighing 60 kg, the daily dose is usually 1 to 2000 mg, preferably 5 to 500 mg. Of course, the specific dosage must also take into account factors such as the route of administration and the patient's health condition, all of which are within the skill of a skilled physician.

[0058] The main advantages of the present invention are: 1. Providing a compound as shown in Formula I: 2. To provide a KAT6 inhibitor with a novel structure that can inhibit KAT6 activity at very low concentrations, as well as its preparation and application. 3. To provide a KAT6 inhibitor with excellent oral absorption. 4. To provide a pharmaceutical composition for treating diseases associated with KAT6 activity.

[0059] Hereinafter, the present invention will be further described in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and do not limit the scope of the present invention. In the following examples, experimental methods without specific conditions are usually in accordance with conventional conditions or conditions suggested by manufacturers. Unless otherwise specified, percentages and parts are calculated by weight.

[0060] Some of the representative compounds of the present invention can be prepared by the following synthetic methods. In each of the following reaction schemes, the reagents and conditions at each step can be selected from conventional reagents or conditions used in the relevant type of preparation method in the art. After the structure of the compound of the present invention is disclosed, a person skilled in the art can make the above selection based on the knowledge in the art.

[0061] General synthesis of compounds Some compounds of the invention can be prepared by the following methods. Reaction Scheme 1: [ka] Compound (VIIIa) can be synthesized using the method of patent WO2020254946, and compound (VIIIb) can be synthesized using the related references. Compound (VIIIa) and compound (VIIIb) are reacted in an inert solvent to obtain compound (VIII). A in the above reaction scheme is as defined in claim 1.

[0062] The compounds of formula (II) of the present invention can be prepared by the following methods. Reaction Scheme 2: [ka] Compound (IIa) can be synthesized using the method of Patent WO2020254946. Compound (IIa) is reacted with compound (IIb) in an inert solvent to obtain compound (IIc), which is then subjected to a metal-catalyzed coupling reaction or substitution reaction with a corresponding intermediate or reagent to synthesize the target compound (II). R in the above reaction scheme 2 , R 3 , R 7 , R 8 , R 9 , R 10 , n, m, h, j, D and E are as in the claims.

[0063] The compounds of formula (III) of the present invention can be prepared by the following methods. Reaction Scheme 3: [ka] In an inert solvent, compound (IIc) and compound (IIIa) are subjected to a coupling reaction or substitution reaction using a metal catalyst to synthesize the target compound (IIIb), and compound (IIIb) is reacted with wittig to obtain compound (III). 2 , R 7 , R 8 , R 9 , R 10 , R 12 , R13 , R 14 , p, q, h, j, m, t, D and U are as defined in the claims.

[0064] The compounds of formula (IV) of the present invention can be prepared by the following methods. Reaction Scheme 4: [ka] In an inert solvent, compound (IIc) and compound (IVa) are subjected to a coupling reaction using a metal catalyst to obtain compound (IV). 2 , R 4 , R 7 , R 8 , R 9 , R 10 , h, j and m are as defined in the claims.

[0065] The compounds of formula (V) of the present invention can be prepared by the following methods. Reaction Scheme 5: [ka]

[0066] In an inert solvent, compound (Va) is reacted with chlorosulfonic acid to obtain compound (Vb), compound (Vb) is reacted with compound (IIa) to obtain compound (Vc), and compound (Vc) is reacted with compound (IIa) to obtain compound (V). 2 , R 6 , R 7 , R 8 , R 9 , R 10 , R h , R i , a, b, f, g, h and j are as defined in the claims.

[0067] The compounds of formula (VI) of the present invention can be prepared by the following methods. Reaction Scheme 6: [ka]

[0068] In an inert solvent, compound (Vb) is reacted with compound (VIa) to obtain compound (VIb), which is then subjected to a Wittig reaction to obtain compound (VIc), which is then deprotected to obtain compound (VId). Compound (VIe) is synthesized using the method of patent WO2020216701. Compound (VId) is reacted with compound (VIe) to obtain compound (VI). R in the above reaction scheme 2 , R 6 , R 11 , R h , R i , X, a, b, g, f and k are as defined in the claims.

[0069] The compounds of formula (VII) of the present invention can be prepared by the following methods. Reaction Scheme 7: [ka]

[0070] In an inert solvent, compound (IIb) is reacted with compound (VIa) to obtain compound (VIIa), which undergoes a metal-catalyzed coupling reaction or substitution reaction to obtain compound (VIIb). Compound (VIIb) is subjected to a Wittig reaction to obtain compound (VIIc), which is then deprotected to obtain compound (VIId). Compound (VIe) is synthesized using the method of patent WO2020216701. Compound (VIId) is reacted with compound (VIe) to obtain compound (VII). R in the above reaction scheme 2 , R 11 , R 12 , R 13 , R 14 , X, D, U, p, q, t, m, and k are as in the claims.

[0071] Working Example: Example 1: Preparation of Compound 1 [ka]

[0072] Compound 1a was synthesized using the method described in patent WO20130158004. Compound 1a (205 mg, 0.80 mmol) was dissolved in tetrahydrofuran (5 mL) and cooled to -78 °C under a nitrogen atmosphere. n-butyllithium (0.35 mL, 2.5 M n-hexane solution) was added dropwise. The reaction mixture was kept warm and stirred for 1 hour. Bis(sulfur dioxide)-1,4-diazabicyclo[2.2.2]octane adduct (115 mg, 0.48 mmol) was added. The reaction mixture was allowed to warm slowly to room temperature and stirred for 1 hour. The reaction mixture was concentrated under reduced pressure, and the residue was washed with methyl t-butyl ether and filtered to obtain solid compound 1b (180 mg, 91%), which was used directly in the next reaction step.

[0073] Compound 1b (203 mg, 0.82 mmol) was dissolved in dichloromethane (5 mL), chlorobutyllactim (109 mg, 0.82 mmol) was added in an ice bath, and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting filtrate was then purified by silica gel column chromatography to give compound 1c (94 mg, 42%) as a white solid. 1 H NMR (500MHz, CDCl3)δ=7.78(d,J=9.0Hz,1H),6.41(d,J=2.0Hz,1H),6.36(dd,J=9.0Hz,J=2.0Hz,1H),4.68- 4.62(m,1H),2.44-2.38(m,2H),2.17-2.10(m,2H),1.89-1.80(dd,J=21.0,10.4,1H),1.72-1.62(m,1H)ppm.

[0074] Compound 1d is synthesized using the method of patent WO2020254946. Compound 1c (30 mg, 0.11 mmol) is dissolved in pyridine (0.2 mL) and compound 1d (13 mg, 0.05 mmol) is added. The reaction mixture is placed in a sealed tube, heated to 120 °C, and stirred for 2 hours. The reaction mixture is concentrated under reduced pressure, separated and purified by preparative thin-layer plate to obtain white solid compound 1 (5 mg, 20%). 1 H NMR (500MHz, CDCl3)δ 8.05-7.94(m,2H),7.60(s,1H),7.46(s,1H),6.79(s,1H),6.50(s,1H),6.42(dd,J=8.8,1.8Hz,1H),6.37-6.31(m,2H),5.41(s ,2H),4.69-4.61(m,1H),3.96(s,3H),3.84(s,3H),2.48-2.38(m,2H),2.19-2.08(m,2H),1.91-1.83(m,1H),1.74-1.65(m,1H). MS m / z 485.4M+H] + .

[0075] Example 2: Preparation of Compound 2 [ka]

[0076] p-Methoxybromobenzene 2a (1.0 g, 5.38 mmol) was dissolved in dichloromethane (10 mL). Chlorosulfonic acid (1.0 mL) was added dropwise in an ice bath, and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture was poured into ice water and extracted three times with dichloromethane (20 mL × 3). The combined organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to give compound 2b (1.4 g, 92%) as a white solid.

[0077] Compound 1d is synthesized using the method of patent WO2020254946. Compound 2b (70 mg, 0.25 mmol) is dissolved in pyridine (0.2 mL) and compound 1d (30 mg, 0.12 mmol) is added. The reaction mixture is placed in a sealed tube and heated and stirred at 120 °C for 2 hours. The reaction mixture is concentrated under reduced pressure, separated and purified by silica gel column chromatography to obtain white solid compound 2c (30 mg, 50%). MS m / z 493.3 [M+H] + .

[0078] Compound 2c (25 mg, 0.05 mmol), (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonate (4 mg, 0.005 mmol), 2-dicyclohexylphosphone-2',6'-diisopropoxy-1,1'-biphenyl (5 mg, 0.01 mmol), sodium t-butoxide (19 mg, 0.20 mmol), and cyclopropylamine hydrochloride (14 mg, 0.15 mmol) were dissolved in 1,4-dioxane (0.5 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere, heated to 90 °C, and stirred for 3 h. The reaction completion was monitored by TLC. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure, separated and purified by preparative thin layer plate to give white solid compound 2 (3 mg, 13%). 1 H NMR (500MHz, CDCl3)δ 8.08(s,1H),7.56(d,J=1.2Hz,1H),7.43(d,J=2.0Hz,1H),7.29(br,1H),6.84(d,J=8.8Hz,1H),6.78(s,1H),6.73(br,1 H),6.44(s,1H),6.31(t,J=1.9Hz,1H),5.37(s,2H),3.95(s,3H),3.95-3.91(m,4H),3.83(s,3H),2.43-2.36(m,2H)ppm. MS m / z 470.4[M+H] + .

[0079] Example 3: Preparation of Compound 3 [ka] Compound 2c (28 mg, 0.06 mmol), trimethylsilylacetylene (11 mg, 0.11 mmol), Pd(dppf)Cl2 (9 mg, 0.01 mmol), tri-t-butylphosphine (6 mg, 0.03 mmol), and copper iodide (2 mg, 0.01 mmol) were dissolved in a mixture of tetrahydrofuran and triethylamine (0.5 mL / 0.5 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated with stirring at 90 °C for 3 h. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The mixture was separated and purified using a preparative thin-layer plate to give compound 3a (9 mg, 31%) as a white solid. MS m / z 511.4 [M+H] + .

[0080] Compound 3a (9 mg, 0.02 mmol) was dissolved in acetonitrile (1 mL) and potassium carbonate (5 mg, 0.04 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure, and the crude product was separated and purified by preparative thin-layer plate separation to give compound 3 (4 mg, 49%) as a white solid. 1 H NMR (500MHz, CDCl3)δ 8.27(d,J=2.1Hz,1H),7.63(dd,J=8.6Hz,J=2.1Hz,1H),7.57(d,J=1.6Hz,1H),7.44(d,J=2.2Hz,1H),6.90(d,J=8. 6Hz,1H),6.79(s,1H),6.45(s,1H),6.32(t,J=2.1Hz,1H),5.38(s,2H),3.96(s,3H),3.92(s,3H),3.07(s,1H)ppm. MS m / z 439.3[M+H] + .

[0081] Example 4: Preparation of Compound 4 [ka]

[0082] Compound 4a (5.0 g, 23.03 mmol) was dissolved in dichloromethane (20 mL), and chlorosulfonic acid (3.0 mL) was added dropwise in an ice bath. The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was poured into ice water and extracted three times with dichloromethane (20 mL × 3). The combined organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to give compound 4b (500 mg) as a white solid. 1 H NMR (500MHz, CDCl3) δ 6.82(s,2H),3.98(s,6H).

[0083] Compound 4b (150 mg, 0.48 mmol) was dissolved in pyridine (0.2 mL) and compound 1d (58 mg, 0.24 mmol) was added. The reaction mixture was placed in a sealed tube, heated to 120 °C, and stirred for 2 h. The reaction mixture was concentrated under reduced pressure, and the resulting crude product was separated and purified by silica gel column chromatography to give compound 4c (55 mg, 44%) as a white solid. MS m / z 523.0 [M+H] + .

[0084] Compound 4c (35 mg, 0.07 mmol), triethylamine (0.2 mL), bis(triphenylphosphine)palladium dichloride (5 mg, 0.007 mmol), and trimethylsilylacetylene (20 mg, 0.21 mmol) were dissolved in dimethyl sulfoxide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated with stirring at 100 °C for 2 h. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica gel column chromatography to give compound 4d (27 mg, 75%) as a white solid. MS m / z 541.2 [M+H] + .

[0085] Compound 4d (27 mg, 0.05 mmol) was dissolved in a mixture of methanol (1 mL) and N,N-dimethylformamide (0.2 mL), and potassium carbonate (35 mg, 0.25 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure, and the crude product was separated and purified by preparative thin-layer plate separation to give compound 4 (14 mg, 61%) as a white solid. MS m / z 469.0 [M+H] + . 1 H NMR (500MHz, CDCl3-d)δ 8.18(s,1H),7.58(d,J=1.9Hz,1H),7.45(d,J=2.3Hz,1H),6.79(s,1H),6.68(s,2H),6.4 5(s,1H),6.33(t,J=2.1Hz,1H),5.39(s,2H),3.96(s,3H),3.87(s,6H),3.21(s,1H)ppm.

[0086] Example 5: Preparation of Compound 5 [ka] Compound 2c (20 mg, 0.04 mmol), sodium t-butoxide (12 mg, 0.12 mmol), (2-dicyclohexylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)methanesulfonate palladium(II) (2.6 mg, 0.003 mmol), 2-dicyclohexylphosphone-2',6'-diisopropoxy-1,1'-biphenyl (2.6 mg, 0.006 mmol), and methylpiperazine (12 mg, 0.12 mmol) were dissolved in dimethylacetamide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated to 85 °C for 3 h with stirring. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 5 was separated and purified by preparative thin-layer plate separation to give a white solid, compound 5 (8 mg, 38%). MS m / z 513.2 [M+H] + . 1H NMR (500MHz, DMSO-d6)δ 9.90(s,1H),7.86(d,J=2.1Hz,1H),7.49(d,J=2.0Hz,1H),7.39(d,J=3.0Hz,1H),7.11(dd,J=9.0,3.0Hz,1H),7.00(d,J=9.0Hz,1H ),6.73(s,1H),6.65(s,1H),6.29(t,J=2.0Hz,1H),5.41(s,2H),3.83(s,3H),3.68(s,3H),3.09(m,4H),2.74(m,4H),2.42(s,3H).

[0087] Example 6: Preparation of Compound 6 [ka] Compound 2c (20 mg, 0.04 mmol), cesium carbonate (40 mg, 0.12 mmol), (2-dicyclohexylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)methanesulfonate palladium(II) (2.6 mg, 0.003 mmol), 2-dicyclohexylphosphone-2',6'-diisopropoxy-1,1'-biphenyl (2.6 mg, 0.006 mmol), and morpholine (11 mg, 0.12 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated to 100 °C for 3 h with stirring. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 6 was separated and purified by preparative thin-layer plate separation to give a white solid, Compound 6 (4 mg, 20%). MS m / z 500.1 [M+H] + . 1H NMR (500MHz, DMSO-d6)δ 10.05(s,1H),7.87(d,J=2.2Hz,1H),7.49(d,J=2.2Hz,1H),7.33(d,J=3.0Hz,1H),7.15(m,2H),6. 78(m,2H),6.30(t,J=2.0Hz,1H),5.43(s,2H),3.83(s,3H),3.73-3.66(m,7H),3.10-2.90(m,4H).

[0088] Example 7: Preparation of Compound 7 [ka] Compound 2c (20 mg, 0.04 mmol), cesium carbonate (40 mg, 0.12 mmol), bis(triphenylphosphine)palladium dichloride (2.8 mg, 0.004 mmol), and cycloproacetylene (8 mg, 0.12 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated with stirring at 100 °C for 2 h. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The mixture was separated and purified by preparative thin-layer plate separation to give compound 6 (5 mg, 26%) as a white solid. MS m / z 479.1 [M+H] + . 1 H NMR (500MHz, DMSO-d6)δ 10.46(s,1H),7.88(d,J=2.0Hz,1H),7.70(d,J=2.0Hz,1H),7.64-7.58(m,1H),7.50(d,J=1.3Hz,1H),7.17(d,J=8.7Hz,1H),6.85(s, 1H),6.75(s,1H),6.31-6.29(m,1H),5.44(s,2H),3.81(s,3H),3.78(s,3H),1.54-1.49(m,1H),0.89-0.83(m,2H),0.73-0.75(m,2H).

[0089] Example 8: Preparation of Compound 8 [ka]

[0090] Compound 2b (140 mg, 0.49 mmol) was dissolved in tetrahydrofuran (5 mL), and ammonia methanol solution (7 M, 1.0 mL, 7 mmol) was added dropwise at room temperature. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the resulting crude product was purified by silica gel column chromatography to give compound 8a (100 mg, 77%) as a white solid.

[0091] Compound 8b was synthesized using the method described in patent WO2020216701. Compound 8a (50 mg, 0.19 mmol), compound 8b (47 mg, 0.21 mmol), and N,N-diisopropylethylamine (107 mg, 0.76 mmol) were dissolved in dichloromethane (2 mL). 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate (130 mg, 0.23 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The white solid compound 8c (50 mg, 59%) was obtained by silica gel column chromatography. MS m / z 453.0 [M+H] + .

[0092] Compound 8c (25 mg, 0.06 mmol), cesium carbonate (54 mg, 0.17 mmol), bis(triphenylphosphine)palladium dichloride (3.9 mg, 0.006 mmol), and cycloproacetylene (11 mg, 0.17 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated with stirring at 100 °C for 2 h. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The mixture was separated and purified by preparative thin-layer plate separation to give compound 8 (11 mg, 46%) as a white solid. MS m / z 439.0 [M+H] + .1 H NMR (500MHz, DMSO-d6)δ 12.55(s,1H),7.91(br,1H),7.80(d,J=2.1Hz,1H),7.63(s,1H),7.55(d,J=8.8Hz,1H),7.18(d,J=7.8Hz,1H),6.85 (d,J=8.8Hz,1H),6.77(s,1H),3.86(s,3H),2.98(s,6H),1.58-1.52(m,1H),0.90-0.87(m,2H),0.80-0.74(m,2H).

[0093] Example 9: Preparation of Compound 9 [ka] Compound 4c (80 mg, 0.15 mmol), propyne (1 M, 0.45 mL), cesium carbonate (149 mg, 0.46 mmol), and bis(triphenylphosphine)palladium dichloride (14 mg, 0.02 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was heated and stirred at 100 °C under a nitrogen atmosphere for 3 h. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (methanol:dichloromethane = 1:20, V:V) to give compound 9 (7 mg, 9%). 1 H NMR (500MHz, DMSO-d6)δ 9.85(s,1H),7.88(d,J=2.1Hz,1H),7.50(d,J=1.4Hz,1H),6.90-6.70(m,4H), 6.30(t,J=2.0Hz,1H),5.44(s,2H),3.84(s,3H),3.74(s,6H),2.07(s,3H)ppm. MS m / z 483.0M+H] + .

[0094] Example 10: Preparation of Compound 10 [ka] Compound 4c (50 mg, 0.10 mmol), cyclopropylacetylene (13 mg, 0.19 mmol), cesium carbonate (93 mg, 0.29 mmol), and bis(triphenylphosphine)palladium dichloride (13 mg, 0.02 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was heated and stirred at 100 °C under a nitrogen atmosphere for 3 h. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (methanol:dichloromethane = 1:20, V:V) to give compound 10 (12 mg, 25%). 1 H NMR (500MHz, DMSO-d6)δ 9.79(brs,1H),7.88(d,J=2.1Hz,1H),7.50(d,J=1.4Hz,1H),6.82(s,1H),6.77-6.68(m,3H),6.30(t,J=2.0 Hz,1H),5.44(s,2H),3.85(s,3H),3.74(s,6H),1.60-1.53(m,1H),0.95-0.89(m,2H),0.80-0.73(m,2H)ppm. MS m / z 508.9[M+H] + .

[0095] Example 11: Preparation of Compound 11 [ka] Compound 11a is synthesized using the method of patent WO200610629. Compound 11a (300 mg, 1.05 mmol) is dissolved in pyridine (1.2 mL) and compound 1d (128 mg, 0.53 mmol) is added. The reaction mixture is placed in a sealed tube, heated to 120 °C, and stirred for 2 hours. The reaction mixture is concentrated under reduced pressure, and the resulting crude product is separated and purified by silica gel column chromatography to obtain white solid compound 11b (100 mg, 39%). MS m / z 494.9 [M+H] + .

[0096] Compound 11b (18 mg, 0.04 mmol), triethylamine (0.2 mL), bis(triphenylphosphine)palladium dichloride (2 mg, 0.003 mmol), and trimethylsilylacetylene (12 mg, 0.12 mmol) were dissolved in dimethyl sulfoxide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated with stirring at 100 °C for 2 h. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL × 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica gel column chromatography to give compound 11c (5 mg, 27%) as a white solid. MS m / z 511.1 [M+H] + .

[0097] Compound 11c (5 mg, 0.01 mmol) was dissolved in methanol (1 mL) and N,N-dimethylformamide (0.2 mL), and potassium carbonate (4 mg, 0.03 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure, and the crude product was separated and purified by preparative thin-layer plate (methanol:dichloromethane = 1:20, V:V) to give compound 11 (2 mg, 47%) as a white solid. 1 H NMR (500MHz, CDCl3)δ 8.08(d,J=8.1Hz,1H),8.02(s,1H),7.57(d,J=1.2Hz,1H),7.43(d,J=2.0Hz,1H),7.20(d,J=8.1Hz,1H),7.03(s ,1H),6.79(s,1H),6.45(s,1H),6.32(t,J=2.0Hz,1H),5.38(s,2H),3.96(s,3H),3.91(s,3H),3.24(s,1H)ppm. MS m / z 439.0[M+H] + .

[0098] Example 12: Preparation of Compound 12 [ka] Compound 11b (18 mg, 0.04 mmol), cesium carbonate (40 mg, 0.12 mmol), bis(triphenylphosphine)palladium dichloride (2.8 mg, 0.004 mmol), and cycloproacetylene (8 mg, 0.12 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated and stirred at 100 °C for 2 h. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL × 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 12 (10 mg, 57%) was separated and purified by preparative thin-layer plate (methanol:dichloromethane = 1:20, V:V) to give a white solid. 1 H NMR (500MHz, DMSO-d6)δ 10.34(s,1H),7.87(d,J=2.1Hz,1H),7.71(d,J=8.1Hz,1H),7.50(d,J=1.6Hz,1H),7.13(s,1H),7.05(d,J=8.1Hz,1H),6.83(s,1H) ,6.73(s,1H),6.30(t,J=2.1Hz,1H),5.44(s,2H),3.81(s,3H),3.76(s,3H),1.58(m,1H),0.97-0.87(m,2H),0.80-0.70(m,2H)ppm. MS m / z 479.1[M+H] + .

[0099] Example 13: Preparation of Compound 13 [ka] Compound 2c (30 m, 0.06 mmol), a tetrahydrofuran solution of propyne (1 M, 0.30 mL), cesium carbonate (60 mg, 0.18 mmol), and bis(triphenylphosphine)palladium dichloride (8 mg, 0.01 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was heated and stirred at 100 °C under a nitrogen atmosphere for 3 h. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (methanol:dichloromethane = 1:20, V:V) to give compound 13 (1.60 mg, 6%). 1 H NMR (500MHz, DMSO-d6)δ 10.50(s,1H),7.87(d,J=1.6Hz,1H),7.73(br,1H),7.62(br,1H),7.49(s,1H),7.18(br,1H), 6.84(br,1H),6.74(br,1H),6.30(s,1H),5.44(s,2H),3.81(s,3H),3.78(s,3H),2.02(s,3H). MS m / z 453.0[M+H] + .

[0100] Example 14: Preparation of Compound 14 [ka] Compound 4c (60 mg, 0.11 mmol), 3-ethynyloxetane (19 mg, 0.23 mmol), cesium carbonate (112 mg, 0.34 mmol), and bis(triphenylphosphine)palladium dichloride (13 mg, 0.12 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was heated and stirred at 100 °C under a nitrogen atmosphere for 2 h. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (methanol:dichloromethane = 1:20, V:V) to give compound 14 (13 mg, 22%). 1H NMR (500MHz, DMSO-d6)δ 9.88(s,1H),7.88(d,J=2.0Hz,1H),7.50(d,J=1.4Hz,1H),6.86-6.80(m,3H),6.76(s,1H),6.30(t,J=2.0Hz,1H),5. 45(s,2H),4.80(dd,J=8.5,5.5Hz,2H),4.62(dd,J=7.0,5.5Hz,2H),4.22-4.14(m,1H),3.85(s,3H),3.77(s,6H)ppm. MS m / z 525.0[M+H] + .

[0101] Example 15: Preparation of Compound 15 [ka] Compound 4c (60 mg, 0.11 mmol), compound 15a (40 mg, 0.34 mmol), cesium carbonate (112 mg, 0.11 mmol), and bis(triphenylphosphine)palladium dichloride (16 mg, 0.02 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was heated and stirred at 100 °C under a nitrogen atmosphere for 2 h. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (methanol:dichloromethane = 1:20, V:V) to give compound 15 (14 mg, 22%). 1 H NMR (500MHz, DMSO-d6)δ 9.90(s,1H),7.89(d,J=2.1Hz,1H),7.50(d,J=1.3Hz,1H),6.83(s,1H),6.80(s,2H),6.76(s,1H),6.31(t,J=2 .0Hz,1H),5.45(s,2H),3.85(s,3H),3.76(s,6H),3.32-3.25(m,1H),3.10-3.00(m,2H),2.81-2.69(m,2H)ppm. MS m / z 559.0[M+H] + .

[0102] Example 16: Preparation of Compound 16 [ka] Compound 11b (28 mg, 0.06 mmol), cesium carbonate (59 mg, 0.18 mmol), bis(triphenylphosphine)palladium dichloride (2 mg, 0.003 mmol), and propyne (24 mg, 0.6 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated and stirred at 100 °C overnight. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL × 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 16 (22 mg, 86%) was separated and purified by preparative thin-layer plate (methanol:dichloromethane = 1:20, V:V) to give a white solid. 1 H NMR (500MHz, CDCl3)δ 8.06-7.97(m,2H),7.57(d,J=1.6Hz,1H),7.43(d,J=2.1Hz,1H),7.08(dd,J=8.1,1.2Hz,1H),6.92(d,J=1.0Hz ,1H),6.79(s,1H),6.44(s,1H),6.32(t,J=2.1Hz,1H),5.38(s,2H),3.96(s,3H),3.88(s,3H),2.05(s,3H)ppm. MS m / z 453.0[M+H] + .

[0103] Example 17: Preparation of Compound 17 [ka] Compound 11b (20 mg, 0.04 mmol), sodium t-butoxide (31 mg, 0.32 mmol), (2-dicyclohexylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)methanesulfonate palladium(II) (2.6 mg, 0.003 mmol), 2-dicyclohexylphosphone-2',6'-diisopropoxy-1,1'-biphenyl (2.6 mg, 0.006 mmol), and compound 2d (19 mg, 0.2 mmol) were dissolved in dimethylacetamide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated to 90 °C for 2 h with stirring. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL × 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The mixture was separated and purified by preparative thin-layer plate (methanol:dichloromethane = 1:20, V:V) to give compound 17 (8 mg, 42%) as a white solid. 1 H NMR (500MHz, CDCl3)δ 7.97(s,1H),7.88(d,J=8.7Hz,1H),7.61(s,1H),7.50(s,1H),6.77(s,1H),6.50(s,1H),6.36(s,1H),5.97(dd ,J=8.7,1.9Hz,1H),5.71(d,J=1.9Hz,1H),5.42(s,2H),3.99-3.92(m,7H),3.83(s,3H),2.47-2.35(m,2H)ppm. MS m / z 470.0[M+H] + .

[0104] Example 18: Preparation of Compound 18 [ka] Compound 18a (1.6 g, 5.11 mmol), potassium thioacetate (875 mg, 7.66 mmol), 1,10-phenanthroline (460 mg, 2.56 mmol), and copper iodide (460 mg, 2.56 mmol) were dissolved in toluene (15 mL), and the reaction mixture was stirred at 100 °C for 20 h. The reaction mixture was quenched with water and extracted three times with ethyl acetate (20 mL × 3). The combined organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography to give compound 18b (1.0 g, 75%) as a reddish-brown solid.

[0105] N-Chlorosuccinimide (2.3 g, 17.2 mmol) was dissolved in a mixture of 2 M aqueous hydrochloric acid (2 mL) and acetonitrile (10 mL), and a solution of compound 18b (1.1 g, 4.2 mmol) in acetonitrile (5 mL) was added dropwise at room temperature. After the addition was complete, the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was quenched with water and extracted three times with ethyl acetate (20 mL x 3). The combined organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude product was purified by silica gel column chromatography to give compound 18c (1.0 g, 83%) as a white solid. 1 H NMR (500MHz, CDCl3) δ 7.47-7.39(m,2H),7.10(dd,J=7.5,2.1Hz,1H),4.05(s,3H).

[0106] Compound 18c (117 mg, 0.41 mmol) was dissolved in pyridine (0.2 mL) to give compound 1d (50 mg, 0.20 mmol). The reaction mixture was placed in a sealed tube, heated to 120 °C, and stirred for 1 h. The reaction mixture was concentrated under reduced pressure, and the resulting crude product was separated and purified by silica gel column chromatography to give compound 18d (50 mg, 50%) as a white solid. MS m / z 492.8 [M+H] + .

[0107] Compound 18d (25 mg, 0.05 mmol), triethylamine (0.2 mL), bis(triphenylphosphine)palladium dichloride (5 mg, 0.007 mmol), and triisopropylsilylacetylene (27 mg, 0.15 mmol) were dissolved in dimethyl sulfoxide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated and stirred at 100 °C overnight. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica gel column chromatography to give compound 18e (25 mg, 83%) as a white solid. MS m / z 595.1 [M+H] + .

[0108] Compound 18e (10 mg, 0.017 mmol) was dissolved in N,N-dimethylformamide (1 mL) and cesium fluoride (15 mg, 0.1 mmol) was added. The reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure, and the resulting crude product was separated and purified using a preparative thin-layer plate (dichloromethane:methanol = 20:1) to give compound 18 (3 mg, 40% yield) as a white solid. MS m / z 439.0 [M+H] + . 1 H NMR (500MHz, CDCl3)δ 8.18(s,1H),7.67(s,1H),7.53(s,1H),7.42(t,J=8.1Hz,1H),7.29(d,J=7.7Hz,1H),6.96(d,J=8.4 Hz,1H),6.83(s,1H),6.66(s,1H),6.40(s,1H),5.49(s,2H),3.99(s,3H),3.91(s,3H),3.58(s,1H).

[0109] Example 19: Preparation of Compound 19 [ka] Compound 4c (25 mg, 0.05 mmol), cesium carbonate (46 mg, 0.14 mmol), bis(triphenylphosphine)palladium dichloride (2.8 mg, 0.004 mmol), and 3-alkynylpyridine (25 mg, 0.24 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated with stirring at 100 °C for 2 h. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL × 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 19 (12 mg, 46%) was separated and purified by preparative thin-layer plate separation (methanol:dichloromethane = 1:20, V:V) to give a white solid. MS m / z 546.1 [M+H] + .

[0110] Example 20: Preparation of Compound 19' [ka] Compound 4b (150 mg, 0.48 mmol) was dissolved in pyridine (0.2 mL) and compound 1d (58 mg, 0.24 mmol) was added. The reaction mixture was placed in a sealed tube, heated to 120 °C, and stirred for 2 h. The reaction mixture was concentrated under reduced pressure, and the resulting crude product was separated and purified by silica gel column chromatography to give compound 19'a (10 mg, 8%) as a white solid. MS m / z 508.9 [M+H] + . Compound 19'a (10 mg, 0.02 mmol), cesium carbonate (19 mg, 0.06 mmol), bis(triphenylphosphine)palladium dichloride (1.4 mg, 0.002 mmol), and 3-alkynylpyridine (10 mg, 0.10 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated with stirring at 100 °C for 2 h. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 19'a was purified by preparative thin-layer plate separation to give a white solid (2 mg, 19%).1 H NMR(500MHz, DMSO-d6)δ 14.01(s,1H),8.77(d,J=1.1Hz,1H),8.60(dd,J=4.8,1.3Hz,1H),8.02 -7.97(m,1H),7.86(d,J=1.6Hz,1H),7.51 -7.44(m,2H),6.69 -6.52(m,4H),6.30(t,J=1.9Hz,1H),5.41(s,2H),3.83(s,3H),3.78(s,3H).MS m / z 532.0[M+H] + .

[0111] Example 21: Preparation of Compound 20 [ka] Compound 4c (30 mg, 0.06 mmol), cesium carbonate (60 mg, 0.18 mmol), bis(triphenylphosphine)palladium dichloride (2.0 mg, 0.003 mmol), and 3-ethynyl-1-azetidinecarboxylic acid (41 mg, 0.23 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated and stirred at 100 °C for 2 h. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL × 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 20 (25 mg, 70%) was isolated and purified by preparative thin-layer plate separation to give a white solid. 1 H NMR(500MHz, DMSO-d6)δ 9.81(s,1H),7.87(d,J=1.6Hz,1H),7.50(d,J=1.0Hz,1H),6.85 -6.80(m,3H),6.75(s,1H),6.34 -6.24(m,1H),5.45(s,2H),4.21 -4.12(m,2H),3.90 -3.81(m,5H),3.77(s,6H),3.73 -3.62(m,1H),1.38(s,9H). MS m / z 624.1[M+H] + .

[0112] Example 22: Preparation of Compound 21 [ka] Compound 20 (7 mg, 0.01 mmol) was dissolved in dichloromethane (1 mL) and trifluoroacetic acid (0.3 mL) was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to give solid compound 21 (6.9 mg, 100%). 1 H NMR (500MHz, DMSO-d6)δ 9.92(s,1H),8.86(s,2H),7.88(d,J=1.7Hz,1H),7.50(d,J=1.1Hz,1H),6.86 -6.72(m,4H),6.30(t,J=1.9Hz,1H),5.45(s,2H),4.31 -4.15(m,2H),4.11 -3.92(m,3H),3.86(s,3H),3.77(s,6H). MS m / z 524.1[M+H] + .

[0113] Example 23: Preparation of Compound 22 [ka] The trifluoroacetate salt of compound 21 (20 mg, 0.03 mmol) was dissolved in dichloromethane (1 mL) and aqueous formaldehyde (0.1 mL, 37%) was added. The reaction mixture was stirred at room temperature for 1 hour, and sodium triacetoxyborohydride (40 mg, 0.19 mmol) was added. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the resulting crude product was separated and purified by preparative thin-layer plate (dichloromethane:methanol = 10:1) to give compound 22 (3 mg, 17% yield) as a white solid. 1 H NMR(500MHz, DMSO-d6)δ 9.82(s,1H),7.87(s,1H),7.50(s,1H),6.92 -6.62(m,4H),6.38 -6.19(m,1H),5.44(s,2H),3.85(s,3H),3.74(s,6H),3.64 -3.57(m,2H),3.48 -3.40(m,1H),3.17 -3.09(m,2H),2.27(s,3H). MS m / z 538.0[M+H] + .

[0114] Example 24: Preparation of Compound 23 [ka] Compound 18d (40 mg, 0.08 mmol), cesium carbonate (80 mg, 0.24 mmol), bis(triphenylphosphine)palladium dichloride (2.8 mg, 0.004 mmol), and 1-(trimethylsilyl)propyne (45 mg, 0.4 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated and stirred at 100 °C for 2 h. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL × 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by preparative thin-layer plate (dichloromethane:methanol = 20:1) to give compound 23 (3 mg, 8%) as a white solid. 1 H NMR(500MHz, CDCl3)δ 8.18(s,1H),7.64(s,1H),7.50(s,1H),7.35(t,J=8.1Hz,1H),7.16(d,J=7.8Hz,1H),6.91 -6.75(m,2H),6.59(s,1H),6.38(s,1H),5.45(s,2H),3.98(s,3H),3.87(s,3H),2.13(s,3H).MS m / z 452.9[M+H] + .

[0115] Example 25: Preparation of Compound 24 [ka]

[0116] Compound 11b (25 mg, 0.05 mmol), cesium carbonate (49 mg, 0.15 mmol), bis(triphenylphosphine)palladium dichloride (2.0 mg, 0.003 mmol), and 3-ethynyl-1-azetidinecarboxylic acid (24a, 28 mg, 0.15 mmol) were dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was placed in a sealed tube under a nitrogen atmosphere and heated with stirring at 100 °C for 2 h. The reaction mixture was quenched with water and extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 24b (20 mg, 67%) was isolated and purified by preparative thin-layer plate separation to give a white solid. MS m / z 594.0 [M+H] + .

[0117] Compound 24b (20 mg, 0.03 mmol) was dissolved in dichloromethane (1 mL) and trifluoroacetic acid (0.3 mL) was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to give solid compound 24c (20 mg, 100%). MS m / z 494.0 [M+H] + .

[0118] Compound 24c (20 mg, 0.03 mmol) was dissolved in dichloromethane (1 mL) and aqueous formaldehyde (0.1 mL, 37%) was added. The reaction mixture was stirred at room temperature for 1 hour, and sodium triacetoxyborohydride (40 mg, 0.19 mmol) was added. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the resulting crude product was separated and purified by preparative thin-layer plate (dichloromethane:methanol = 10:1) to give compound 24 (3 mg, 18% yield) as a white solid. 1H NMR(500MHz, DMSO)δ 10.19(br,1H),7.85(d,J=2.2Hz,1H),7.74(d,J=8.0Hz,1H),7.50 -7.46(m,1H),7.08 -7.04(m,1H),7.01(dd,J=8.0,1.3Hz,1H),6.66(s,1H),6.60(s,1H),6.28(t,J =2.0Hz,1H),5.39(s,2H),3.92(t,J=7.6Hz,2H),3.81(s,3H),3.74(s,3H),3.69 -3.61(m,1H),3.61 -3.52(m,2H),2.52(s,3H). MS m / z 508.0[M+H] + .

[0119] Example 26: Inhibition of compound KAT6A enzyme activity: Prepare 1x experimental buffer (modified Tris buffer) and prepare compounds to a 10 mM stock solution in 100% DMSO, then dilute them according to a concentration gradient. Transfer the compounds to a 384-well plate using the Echo autosampler, with the final DMSO concentration at 1%. Prepare 1x KAT6A enzyme (catalytic domain) solution. Prepare a mixed solution of [3H]-acetyl coenzyme A (PERKIN ELMER, Cat. No. NET290250UC) and substrate peptide segment H3 (1-21). Transfer 10 μL of the enzyme solution to a 384-well plate and incubate at room temperature for 15 minutes. Add 10 μL of the mixed solution of [3H]-acetyl coenzyme A and substrate peptide segment H3 (1-21) to the well to initiate the reaction. Incubate at room temperature for 1 hour. Add 10 μL of stop solution to stop the reaction. Transfer 25 μL of the reaction solution to a Flashplate (Perkin Elmer, Cat. No. SMP410A001PK) and incubate at room temperature for 1 hour. Read the plate using a Microbeta. Calculate the inhibition rate of the compound using Excel using the formula: Inhibition % = (Max - Signal) / (Max - Min) x 100%, where max refers to the value of the DMSO control, min refers to the value of the control without enzyme activity, and signal refers to the value of the test compound well. Use XLFit software to fit the curve and calculate the IC 50 The activities of some representative compounds are shown in Table 1. [Table 1]

[0120] Example 27: Pharmacokinetic study in rats Instrument: Waters XEVO TQ-S liquid mass spectrometer. All measurement data were collected and processed by Masslynx V4.1 software, and Microsoft Excel was used for data calculation and processing. WinNonLin 8.0 software was used to calculate pharmacokinetic parameters using the statistical method of moments. This mainly involves the kinetics parameter T. max , T 1 / 2 , C max , AUC 0-24h Chromatography column: ACQUITY UPLC BEH C18 (2.1 mm × 50 mm, 1.7 μm), column temperature: 40°C, mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile, flow rate: 0.350 mL / min, gradient elution: 0.50 min: 10% B, 1.50 min: 90% B, 2.50 min: 90% B, 2.51 min: 10% B, 3.50 min: stop. Injection volume: 1 μL.

[0121] Animals: Three SD male rats, weighing 200-220g, were purchased and housed in the laboratory of the Experimental Animal Center for two days before use. They were fasted for 12 hours before administration and for four hours after administration, but had free access to water throughout the study. After intragastric administration, blood samples were collected from the rats at designated time points.

[0122] Solvent: 0.4% ethanol + 0.4% Tween 80 + 99.2% (0.5% methylcellulose M450). Preparation of intragastric solution: Accurately weigh the compound, add it to the solvent, and sonicate at room temperature for 5 minutes to completely dissolve the drug, preparing a 0.3 mg / mL drug solution.

[0123] Drug samples: Generally, multiple samples with similar structures (with molecular weights differing by at least two units) are collected, accurately weighed, and administered together (cassette PK). This allows multiple compounds to be screened simultaneously and their oral absorption rates compared. A single dose is used to study the pharmacokinetics of the drug sample in rats.

[0124] Blood was collected via the orbit at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours after intragastric administration. 50 μL of plasma samples were collected, and 200 μL of acetonitrile (containing 2 ng / mL of verapamil as an internal standard) was added. The samples were vortexed for 3 minutes, then centrifuged at 20,000 rcf for 10 minutes at 4°C. The supernatant was collected and analyzed by LC-MS / MS.

[0125] The compound is accurately weighed, prepared at various concentrations, and quantitatively analyzed by a mass spectrometer to generate a standard curve. The concentration of the compound in the plasma is then tested to obtain the concentration of the compound at different time points. All measurement data are collected and processed by the associated software, and the statistical method of moments is used to calculate pharmacokinetic parameters (mainly the dynamics parameter T). max , T 1 / 2 , C max , AUC 0-24h The dynamics parameters of some representative compounds are shown in Table 2. [Table 2]

[0126] All documents mentioned in this application are incorporated by reference in this application as if each document were incorporated by reference individually. Furthermore, after reading the above teachings of the present invention, those skilled in the art will be able to make various changes or modifications to the present invention, and these equivalents will also fall within the scope defined by the appended claims of this application.

Claims

1. A compound represented by the following formula (I), or an optical isomer, pharmaceutically acceptable salt, deuterated derivative, hydrate, or solvate thereof: 【Chemical 1】 The compound of formula (I) is represented by any one of the structures of formula (III), formula (IV), or formula (V), 【Chemistry 2】 【Chemistry 3】 【Chemistry 4】 U is selected from N or CR k , where R k is selected from hydrogen, halogen, and C 1-4 alkyl groups; each R 14 is independently selected from hydrogen, halogen, a C 1-4 alkyl group, a C 1-4 halogenated alkyl group, CN, OR b , SR b , and NR b R b ; p and q are each independently selected from 0, 1, 2, 3, 4, 5, or 6, provided that p and q cannot simultaneously be selected from 0; t is selected from 0, 1, 2, 3, or 4; Each R ２ are each independently hydrogen, halogen, or C １－４ Alkyl group, C １－４ Halogenated alkyl group, C １－４ Alkoxy C １－４ Alkyl group, C １－４ Halogenated alkoxy C １－４ Alkyl group, C ２－４ Alkenyl group, C ２－４ Halogenated alkenyl group, C ２－４ Alkynyl group, C ３－６ Cycloalkyl groups, 3- to 8-membered heterocyclic groups, aryl groups, heteroaryl groups, CN, OR ａ , S.R. ａ , or NR ａ R ａ wherein each R ａ are each independently hydrogen, C １－４ Alkyl group, C １－４ Halogenated alkyl group, C ３－６ a cycloalkyl group, or a 3- to 8-membered heterocyclic group; D is a chemical bond, —O—, —S—, or —NR ｅ -, where R ｅ is hydrogen, C １－４ alkyl group, or C ３－６ cycloalkyl groups, and E is selected from C ３－８ Cycloalkyl group, 3- to 10-membered heterocyclic group, C ３－８ Cycloalkyl C １－４ Alkyl group, or 3- to 10-membered heterocyclic ring C １－４ alkyl groups, Here, R １２ and R １３ are each independently hydrogen, fluorine, or C １－４ alkyl groups, and １２ or R １３ The alkyl group above is halogen, C １－４ Halogenated alkyl group, CN, OR ｂ , S.R. ｂ , N.R. ｂ R ｂ , C ３－６ and each R is optionally substituted with one or more groups selected from the group consisting of a cycloalkyl group, a 3- to 8-membered heterocyclic group, an aryl group, or a heteroaryl group. ｂ are each independently hydrogen, C １－４ alkyl group, or C １－４ selected from halogenated alkyl groups, R 4 is hydrogen, C １－４ Alkyl group, C ３－８ is selected from the group consisting of a cycloalkyl group, a 3- to 9-membered heterocyclic group, an aryl group, or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group, or the heteroaryl group is selected from the group consisting of a halogen, CN, OR ａ , S.R. ａ , N.R. ａ R ａ , NO ２ , -C(O)R ｍ , -C(O)OR ａ , -S(O) ２ R ｍ , —C(O)NR ａ R ａ , -OC(O)R ｍ , -NR ａ C(O)R ｍ , -NR ａ S (O) ２ R ｍ , C １－４ Alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, C ３－６ optionally substituted with one or more groups selected from the group consisting of a cycloalkyl group, a 3- to 8-membered heterocyclic group, an aryl group, or a heteroaryl group, or the cycloalkyl group or heterocyclic group is substituted with =T, wherein each R ａ is as defined above, and R ｍ is C １－４ Alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, C ３－６ cycloalkyl groups, T is selected from CR 12 R 13 ; Each R ６ are each independently hydrogen, halogen, or C １－４ Alkyl group, C １－４ Halogenated alkyl group, CN, OR ｂ , S.R. ｂ , or NR ｂ R ｂ where each R ｂ is as defined above, Here, R ｈ and R ｉ are each independently hydrogen, fluorine, or C １－４ alkyl groups, wherein the alkyl groups are selected from halogen, C １－４ Halogenated alkyl group, CN, OR ｂ , S.R. ｂ , N.R. ｂ R ｂ , C ３－６ and optionally substituted with one or more groups selected from the group consisting of a cycloalkyl group, a 3- to 8-membered heterocyclic group, an aryl group, or a heteroaryl group, wherein each R ｂ is as defined above, Each R ７ are each independently hydrogen, halogen, or C １－４ Alkyl group, C １－４ Halogenated alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, CN, OR ａ , S.R. ａ , N.R. ａ R ａ , C ３－６ a cycloalkyl group, a 3- to 8-membered heterocyclic group, an aryl group, a heteroaryl group, or a heteroaryl C １－４ alkyl groups, where each R ａ is as defined above, R ８ and R ９ are each independently hydrogen, fluorine, or C １－４ Alkyl group, C １－４ an alkoxy group, a hydroxy group, or C ３－６ cycloalkyl groups or R ８ and R ９ together with the carbon atoms to which they are attached form a 3- to 6-membered ring structure, which ring structure optionally contains 0, 1, or 2 heteroatoms selected from N, O, and S; Each R １０ are each independently hydrogen, halogen, or C １－４ Alkyl group, C １－４ Halogenated alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, C ３－６ Cycloalkyl group, 3- to 8-membered heterocyclic group, CN, OR ａ , S.R. ａ , or NR ａ R ａ where each R ａ is as defined above, m is selected from 0, 1, 2, 3, or 4; f is selected from 0, 1, 2, or 3; g is selected from 0, 1, 2, 3, or 4; a and b are each independently selected from 0, 1, 2, 3, 4, or 5, with the proviso that a and b cannot simultaneously be selected from 0; h is selected from 0, 1, 2, or 3; j is selected from 0, 1, 2, or 3; wherein each of the alkyl group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclic group, aryl group and heteroaryl group optionally and independently may further include halogen, C １－４ Alkyl group, C １－４ Halogenated alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, C ３－８ Cycloalkyl groups, 3- to 8-membered heterocyclic groups, aryl groups, heteroaryl groups, CN, NO ２ , OR ｂ , S.R. ｂ , N.R. ｄ R ｄ , -C(O)R ｇ , -C(O)OR ｂ , —C(O)NR ｄ R ｄ , -NR ｄ C(O)R ｇ , -NR ｄ S (O) ２ R ｇ , or -S(O) ２ R ｇ and wherein R is substituted by 1 to 3 substituents each independently selected from the group consisting of ｂ , R ｄ , and R ｇ is as defined above, Unless otherwise specified, the aryl group is an aromatic group containing 6 to 12 carbon atoms, the heteroaryl group is a 5 to 15 membered heteroaromatic group, and the ring structure is a saturated or unsaturated ring group with or without heteroatoms.

2. Formula (I) is formula (III): 【Chemistry 5】 U, R 14 , p, q, t, R 2, R ７ , R ８ , R ９ , R １０ , R １２ , R １３ , D, m, h and j are as defined in claim 1. The compound of claim 1.

3. Formula (I) is formula (IV): 【Chemistry 6】 R ２ , R ４ , R ７ , R ８ , R ９ , R １０ , m, h and j are as defined in claim 1. The compound of claim 1.

4. Formula (I) is formula (V), 【Chemistry 7】 R ２ , R ６ , R ７ , R ８ , R ９ , R １０ , R ｈ , R ｉ , a, b, f, g, h and j are as defined in claim 1. The compound of claim 1.

5. Formula (I) is formula (VIII): 【Chemistry 8】 Each R ２ are each independently hydrogen, halogen, or C １－４ Alkyl group, C １－４ Halogenated alkyl group, C ２－４ Alkynyl group, C ３－６ Cycloalkyl group, CN, OR ａ , S.R. ａ , or NR ａ R ａ wherein each R ａ are each independently hydrogen, C １－４ Alkyl group, C １－４ Halogenated alkyl group, C ３－６ cycloalkyl groups, and m is selected from 0, 1, or 2; R ４ , R ７ , R ８ , R ９ , R １０ , h and j are as defined in claim 1. The compound of claim 1.

6. Formula (I) is formula (IX), 【Chemistry 9】 Each R ２ are each independently hydrogen, halogen, or C １－４ Alkyl group, C １－４ Halogenated alkyl group, C ３－６ a cycloalkyl group, or OR ａ is selected from the group consisting of R ４ is hydrogen, C １－４ Alkyl group, C ３－８ is selected from the group consisting of a cycloalkyl group, a 3- to 9-membered heterocyclic group, an aryl group, or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group, or the heteroaryl group is selected from the group consisting of a halogen, CN, OR ａ , S.R. ａ , N.R. ａ R ａ , -C(O)R ｍ , -C(O)OR ａ , -S(O) ２ R ｍ , C １－４ Alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, C ３－６ It is optionally substituted with one or more groups selected from the group consisting of a cycloalkyl group, a 3- to 6-membered heterocyclic group, an aryl group, or a heteroaryl group, or the cycloalkyl group or heterocyclic group is substituted with =T, where T is O or CR １２ R １３ where R １２ and R １３ are each independently hydrogen, fluorine, or C １－４ alkyl groups, and １２ or R １３ The alkyl group above is halogen, C １－４ Halogenated alkyl group, CN, OR ｂ , S.R. ｂ , N.R. ｂ R ｂ and optionally substituted with one or more groups selected from the group consisting of Each R ａ are each independently hydrogen, C １－４ Alkyl group, C １－４ Halogenated alkyl group, C ３－６ cycloalkyl groups, and each R ｂ are each independently hydrogen, C １－４ alkyl group, or C １－４ halogenated alkyl groups; R ｍ is C １－４ Alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, C ３－６ cycloalkyl groups. The compound of claim 1.

7. Formula (I) is formula (X): 【Chemistry 10】 Each R ２ are each independently hydrogen, halogen, or C １－４ Alkyl group, C １－４ Halogenated alkyl group, C ３－６ a cycloalkyl group, or OR ａ is selected from the group consisting of R ４ is hydrogen, C １－４ Alkyl group, C ３－８ is selected from the group consisting of a cycloalkyl group, a 3- to 9-membered heterocyclic group, an aryl group, or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group, or the heteroaryl group is selected from the group consisting of a halogen, CN, OR ａ , S.R. ａ , N.R. ａ R ａ , -C(O)R ｍ , -C(O)OR ａ , -S(O) ２ R ｍ , C １－４ Alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, C ３－６ It is optionally substituted with one or more groups selected from the group consisting of a cycloalkyl group, a 3- to 6-membered heterocyclic group, an aryl group, or a heteroaryl group, or the cycloalkyl group or heterocyclic group is substituted with =T, where T is O or CR １２ R １３ where R １２ and R １３ are each independently hydrogen, fluorine, or C １－４ alkyl groups, and １２ or R １３ The alkyl group above is halogen, C １－４ Halogenated alkyl group, CN, OR ｂ , S.R. ｂ , N.R. ｂ R ｂ and optionally substituted with one or more groups selected from the group consisting of Each R ａ are each independently hydrogen, C １－４ Alkyl group, C １－４ Halogenated alkyl group, C ３－６ cycloalkyl groups, and each R ｂ are each independently hydrogen, C １－４ alkyl group, or C １－４ halogenated alkyl groups; R ｍ is C １－４ Alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, C ３－６ cycloalkyl groups. The compound of claim 1.

8. Formula (I) is formula (XI), 【Chemistry 11】 Each R ２ are each independently hydrogen, halogen, or C １－４ Alkyl group, C １－４ Halogenated alkyl group, C １－４ Alkoxy C １－４ Alkyl group, C １－４ Halogenated alkoxy C １－４ Alkyl group, C ２－４ Alkenyl group, C ２－４ Halogenated alkenyl group, C ２－４ Alkynyl group, C ３－６ Cycloalkyl groups, 3- to 8-membered heterocyclic groups, aryl groups, heteroaryl groups, CN, OR ａ , S.R. ａ , or NR ａ R ａ is selected from the group consisting of R ４ is hydrogen, C １－４ Alkyl group, C ３－６ cycloalkyl groups, wherein said alkyl or cycloalkyl groups are selected from the group consisting of halogen, CN, OR ａ , S.R. ａ , or NR ａ R ａ and optionally substituted with one or more groups selected from the group consisting of Each R ａ are each independently hydrogen, C １－４ Alkyl group, C １－４ Halogenated alkyl group, C ３－６ cycloalkyl groups, m is selected from 0, 1, 2, or 3; The compound of claim 1.

9. Formula (I) is formula (XII): 【Chemistry 12】 R ２ and R ４ is as defined in claim 6 The compound of claim 1.

10. below: 【Chemistry 13】 【Chemistry 14】 【Chemistry 15】 【Chemistry 16】 is selected from the group consisting of The R ２ 2. The compound according to claim 1, wherein is selected from H or OMe.

11. The following: 【Chemistry 17】 A compound, or an optical isomer, pharmaceutically acceptable salt, deuterated derivative, hydrate, or solvate thereof, characterized in that it is selected from the group consisting of:

12. 1. A pharmaceutical composition comprising:

12. A pharmaceutical composition comprising the compound of any one of claims 1 to 11, or an optical isomer, pharmaceutically acceptable salt, deuterated derivative, hydrate, or solvate thereof, and a pharmaceutically acceptable carrier.

13. Use of a compound according to any one of claims 1 to 11, or an optical isomer, pharmaceutically acceptable salt, deuterated derivative, hydrate or solvate thereof, comprising: The use as described above, characterized in that it is used for preparing a pharmaceutical composition for treating a disease, illness or condition associated with KAT6 activity or expression level.

14. The disease, condition, or pathological state is selected from the group consisting of various solid tumors and hematological tumors, such as non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, colon cancer, thyroid cancer, embryonal rhabdomyosarcoma, cutaneous granular cell tumor, melanoma, hepatocellular carcinoma, intrahepatic bile duct cancer, rectal cancer, bladder cancer, pharyngeal cancer, breast cancer, vaginal cancer, prostate cancer, testicular cancer, brain tumor, glioma, ovarian cancer, head and neck squamous cell carcinoma, cervical cancer, osteosarcoma, esophageal cancer, kidney cancer, skin cancer, gastric cancer, myeloid leukemia, lymphocytic leukemia, myelofibrosis, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, monocytic leukemia, splenomegaly, eosinophilic leukocytosis, and bone marrow cancer.

14. The use according to claim 13.

Images